14598 Federal Register / Vol. 72, No.
59 / Wednesday, March 28, 2007 / Notices
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page: http://
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1513 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associate with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Drug Abuse Special Emphasis Panel, Clinical
Trails Network Services.
Date: April 18–19, 2007.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
proposals.
Place: Courtyard by Marriott Rockville,
2500 Research Boulevard, Rockville, MD
20850.
Contact Person: Lyle Furr, Contract Review
Specialist, Office of Extramural Affairs,
sroberts on PROD1PC70 with NOTICES
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
435–1439, if33c.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, Web-
VerDate Aug<31>2005 17:09 Mar 27, 2007 Jkt 211001
Based Core Competency Training for
Coalitions.
Date: April 27, 2007.
Time: 9:30 a.m. to 11:30 a.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6101
Execution Boulevard, Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Nadine Rogers, Health
Scientist Administrator, Office of Extramural
Affairs, National Institute on Drug Abuse,
NIH, DHHS, Room 220, MSC 8401, 6101
Executive Boulevard, Bethesda, MD 20892–
8401, (301) 402–2105, roersn2@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 92.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1514 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering, May Council.
Date: May 16, 2007.
Time: 8:30 a.m. to 1:15 p.m.
PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 E:\FR\FM\28MRN1.SGM
Agenda: Report from the Institute Director,
other Institute Staff and presentations of
working group reports.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Closed: 1:15 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Anthony Demsey, PhD,
Director, Office of Extramural Policy,
National Institute of Biomedical Imaging and
Bioengineering, 6701 Democracy Blvd.,
Room 241, Bethesda, MD 20892.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: http://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agency and any
additional information for the meeting will
be posted when applicable.
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1517 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel Ancillary Studies to
Major Ongoing NIDDK and NHLBI Clinical
Research Studies PAR–06–216.
Date: April 9, 2007.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
28MRN1